治愈儿童急性淋巴细胞白血病的 50 年历程。
A 50-year journey to cure childhood acute lymphoblastic leukemia.
机构信息
Departments of Oncology and Pharmaceutical Sciences, St. Jude Children's Research Hospital.
出版信息
Semin Hematol. 2013 Jul;50(3):185-96. doi: 10.1053/j.seminhematol.2013.06.007.
The 50th anniversary of Seminars in Hematology coincides with the 50th anniversary of St. Jude Children's Research Hospital, and both milestones are inexorably linked to studies contributing to the cure of childhood acute lymphoblastic leukemia (ALL). We thought it fitting, therefore, to mark these events by traveling back in time to point out some of the achievements, institutions, study groups, and individuals that have made cure of childhood ALL a reality. In many instances, progress was driven by new ideas, while in others it was driven by new experimental tools that allowed more precise assessment of the biology of leukemic blasts and their utility in selecting therapy. We also discuss a number of contemporary advances that point the way to exciting future directions. Whatever pathways are taken, a clear challenge will be to use emerging genome-based or immunologic-based treatment options in ways that will enhance, rather than duplicate or compromise, recent gains in outcome with classic cytotoxic chemotherapy. The theme of this journey serves as a reminder of the chief ingredient of any research directed to a catastrophic disease such as ALL. It is the audacity of a small group of investigators who confronted a childhood cancer with the goal of cure, not palliation, as their mindset.
《血液学研讨会》创刊 50 周年与圣裘德儿童研究医院(St. Jude Children's Research Hospital)成立 50 周年不期而遇,这两个里程碑都与促进儿童急性淋巴细胞白血病(ALL)治愈的研究息息相关。因此,我们认为,通过回顾历史,指出一些成就、机构、研究小组和个人,来纪念这些事件是恰当的,这些成就使治愈儿童 ALL 成为现实。在许多情况下,进展是由新的想法推动的,而在其他情况下,是由新的实验工具推动的,这些工具允许更精确地评估白血病细胞的生物学特性及其在选择治疗方法中的应用。我们还讨论了一些当代的进展,这些进展为令人兴奋的未来方向指明了道路。无论选择什么途径,一个明显的挑战将是利用新兴的基于基因组或免疫的治疗选择,以增强而不是复制或损害经典细胞毒性化疗的近期成果。这次旅行的主题提醒我们,任何针对 ALL 等灾难性疾病的研究都需要一个关键因素。这是一小群研究人员的勇气,他们以治愈而不是缓解为目标,直面儿童癌症。